Literature DB >> 16723599

In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.

Paul A Wickman1, Jennifer A Black, Ellen Smith Moland, Kenneth S Thomson.   

Abstract

The in vitro activity of the novel quinolone DX-619 was compared to those of currently available quinolones against U.S. clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp., Streptococcus pyogenes, and Streptococcus pneumoniae. DX-619 was the most potent quinolone overall, indicating possible utility as an anti-gram-positive quinolone.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16723599      PMCID： PMC1479102          DOI： 10.1128/AAC.00011-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001.

Authors: 
Journal:  Am J Infect Control       Date:  2001-12       Impact factor: 2.918

2.  Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

Authors:  G V Doern; K P Heilmann; H K Huynh; P R Rhomberg; S L Coffman; A B Brueggemann
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

Authors: 
Journal:  Am J Infect Control       Date:  2003-12       Impact factor: 2.918

4.  The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.

Authors:  S S Richter; K P Heilmann; S E Beekmann; N J Miller; C L Rice; G V Doern
Journal:  Clin Infect Dis       Date:  2004-12-21       Impact factor: 9.079

5.  In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.

Authors:  Katsuko Fujikawa; Megumi Chiba; Mayumi Tanaka; Kenichi Sato
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Diekema; M A Pfaller; F J Schmitz; J Smayevsky; J Bell; R N Jones; M Beach
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

7.  Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

Authors:  Tatiana Bogdanovich; Duygu Esel; Linda M Kelly; Bülent Bozdogan; Kim Credito; Gengrong Lin; Kathy Smith; Lois M Ednie; Dianne B Hoellman; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

Authors:  Angela B Brueggemann; Stacy L Coffman; Paul Rhomberg; Holly Huynh; Laurel Almer; Angela Nilius; Robert Flamm; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones.

Authors:  Deborah J Griggs; Herida Marona; Laura J V Piddock
Journal:  J Antimicrob Chemother       Date:  2003-04-25       Impact factor: 5.790

10.  Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model.

Authors:  Mendel E Singer; Ian Harding; Michael R Jacobs; Dena H Jaffe
Journal:  J Antimicrob Chemother       Date:  2003-04-14       Impact factor: 5.790
  10 in total
  3 in total

1.  Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.

Authors:  Nenad Sarapa; Prachi Wickremasingha; Nanxiang Ge; Richard Weitzman; Merynda Fuellhart; Cindy Yen; Julia Lloyd-Parks
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

Review 2.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America.

Authors:  Stanford T Shulman; Alan L Bisno; Herbert W Clegg; Michael A Gerber; Edward L Kaplan; Grace Lee; Judith M Martin; Chris Van Beneden
Journal:  Clin Infect Dis       Date:  2012-09-09       Impact factor: 9.079
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.